Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy

G. Piperno; M. Cosimelli; R. Perrone Donnorso; R. Mancini; S. Buglioni; F. Novelli; I. Sperduti; V. Zerbini; C. Garufi; Marcella Mottolese

Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy

G. Piperno, M. Cosimelli, R. Perrone Donnorso, R. Mancini, S. Buglioni, F. Novelli, I. Sperduti, V. Zerbini, C. Garufi, Marcella Mottolese

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.

Original language	English
Pages (from-to)	11-14
Number of pages	4
Journal	Journal of Chemotherapy
Volume	16
Issue number	SUPPL. 5
Publication status	Published - Nov 2004

Keywords

Adjuvant therapy
Advanced rectal cancer
Bcl-2
p53
Prognosis

ASJC Scopus subject areas

Pharmacology (medical)
Microbiology (medical)

Fingerprint Dive into the research topics of 'Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy'. Together they form a unique fingerprint.

Cite this

Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy. / Piperno, G.; Cosimelli, M.; Donnorso, R. Perrone; Mancini, R.; Buglioni, S.; Novelli, F.; Sperduti, I.; Zerbini, V.; Garufi, C.; Mottolese, Marcella.

In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 5, 11.2004, p. 11-14.

Research output: Contribution to journal › Article › peer-review

@article{4edd79c37d074d8d9b76bc1c7ca847fb,

title = "Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy",

abstract = "Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.",

keywords = "Adjuvant therapy, Advanced rectal cancer, Bcl-2, p53, Prognosis",

author = "G. Piperno and M. Cosimelli and Donnorso, {R. Perrone} and R. Mancini and S. Buglioni and F. Novelli and I. Sperduti and V. Zerbini and C. Garufi and Marcella Mottolese",

year = "2004",

month = nov,

language = "English",

volume = "16",

pages = "11--14",

journal = "Journal of Chemotherapy",

issn = "1120-009X",

publisher = "Maney Publishing",

number = "SUPPL. 5",

}

TY - JOUR

T1 - Role of p53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy

AU - Piperno, G.

AU - Cosimelli, M.

AU - Donnorso, R. Perrone

AU - Mancini, R.

AU - Buglioni, S.

AU - Novelli, F.

AU - Sperduti, I.

AU - Zerbini, V.

AU - Garufi, C.

AU - Mottolese, Marcella

PY - 2004/11

Y1 - 2004/11

N2 - Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.

AB - Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.

KW - Adjuvant therapy

KW - Advanced rectal cancer

KW - Bcl-2

KW - p53

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=19944427939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427939&partnerID=8YFLogxK

M3 - Article

C2 - 15675468

AN - SCOPUS:19944427939

VL - 16

SP - 11

EP - 14

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 5

ER -